Trial · NCT01928771
Results by group140
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 140
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL | Benralizumab 30 mg q.4 Weeks | 0.73 | 95% Confidence Interval 0.60 to 0.89 | events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL | Benralizumab 30 mg q.8 Weeks | 0.65 | 95% Confidence Interval 0.53 to 0.80 | events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils >=300/uL | Placebo | 1.33 | 95% Confidence Interval 1.12 to 1.58 | events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL | Benralizumab 30 mg q.4 Weeks | 0.85 | 95% Confidence Interval 0.65 to 1.11 | events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL | Benralizumab 30 mg q.8 Weeks | 1.00 | 95% Confidence Interval 0.78 to 1.28 | events/year | |
| Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Eosinophils < 300/uL | Placebo | 1.21 | 95% Confidence Interval 0.96 to 1.52 | events/year | |
| Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations | Benralizumab 30 mg q.4 Weeks | 0.11 | 95% Confidence Interval 0.07 to 0.16 | events/year | |
| Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations | Benralizumab 30 mg q.8 Weeks | 0.06 | 95% Confidence Interval 0.04 to 0.11 | events/year | |
| Annual Asthma Exacerbation Rate Resulting Emergency Room Visits and Hospitalizations | Placebo | 0.18 | 95% Confidence Interval 0.13 to 0.25 | events/year | |
| Number of Patients With >=1 Asthma Exacerbations | Benralizumab 30 mg q.4 Weeks | 100 | 84.227 | Participants | |
| Number of Patients With >=1 Asthma Exacerbations | Benralizumab 30 mg q.8 Weeks | 93 | 72.002 | Participants | |
| Number of Patients With >=1 Asthma Exacerbations | Placebo | 135 | 74.434 | Participants | |
| Time to First Asthma Exacerbation | Benralizumab 30 mg q.4 Weeks | NA | 95% Confidence Interval 84.227 | Days | |
| Time to First Asthma Exacerbation | Benralizumab 30 mg q.8 Weeks | NA | 95% Confidence Interval 72.002 | Days | |
| Time to First Asthma Exacerbation | Placebo | 300 | 95% Confidence Interval 74.434 | Days | |
| Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.4 Weeks | 0.353 | Standard Deviation 0.503 | Liter | |
| Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL | Benralizumab 30 mg q.8 Weeks | 0.398 | Standard Deviation 0.546 | Liter | |
| Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils >=300/uL | Placebo | 0.237 | Standard Deviation 0.508 | Liter | |
| Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL | Benralizumab 30 mg q.4 Weeks | 0.115 | Standard Deviation 0.417 | Liter | |
| Mean Change From Baseline to Week 48 in Pre-bronchodilator FEV1 (L) Value for Baseline Eosinophils <300/uL | Benralizumab 30 mg q.8 Weeks | 0.238 | Standard Deviation 0.483 | Liter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01928771/results